Regeneron

Regeneron Pharmaceuticals to expand headquarters, create 400 jobs

Friday, April 5, 2013 11:07 AM

Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, N.Y., will expand its corporate headquarters and create more than 400 new high-skill jobs. 

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Sanofi, Regeneron share results for lipid-lowering PCSK9 antibody

Tuesday, March 27, 2012 06:34 AM

Sanofi and Regeneron Pharmaceuticals have reported promising data from two phase II trials with SAR236553/REGN727—an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

More... »

Regeneron, Bayer initiate phase III SIGHT trial in China

Monday, November 28, 2011 10:30 AM

Regeneron Pharmaceuticals and Bayer HealthCare have initiated a phase III clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

More... »

FDA approves EYLEA injection

Monday, November 21, 2011 09:27 AM

The FDA has approved Regeneron Pharmaceuticals' EYLEA (aflibercept) injection for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

More... »

Regeneron names LaRosa senior VP

Tuesday, September 6, 2011 12:44 PM

Regeneron Pharmaceuticals has named Joseph J. LaRosa senior vice president, general counsel and secretary. LaRosa will be responsible for overseeing all legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

More... »

Sanofi, Regeneron announce trial results

Friday, July 15, 2011 10:19 AM

Sanofi and Regeneron Pharmaceuticals announced results from phase IIb trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R).

More... »

ZALTRAP trial recommended for advancement

Friday, July 8, 2011 12:58 PM

Regeneron Pharmaceuticals has announced that its phase III VENICE clinical trial evaluating the investigational agent ZALTRAP (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns.  This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

More... »

Regeneron/Bayer reveal positive results for CRVO study

Friday, April 29, 2011 11:22 AM

Regeneron Pharmaceuticals and Bayer HealthCare reveal positive results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the phase III GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). 

More... »

Sanofi, Regeneron show positive results for Zaltrap

Wednesday, April 27, 2011 02:13 PM

Partners Sanofi-Aventis and Regeneron Pharmaceuticals report positive results for a late stage study evaluating Zaltrap (aflibercept), a colorectal cancer candidate.  

More... »